ASH Annual Meeting

ASH Annual Meeting

Highlights and interviews from the American Society of Hematology’s Annual Meeting

For Older Patients With CLL, Ibrutinib-Based Treatment Beats Standard Chemoimmunotherapy

Results from a randomized phase III study indicate that the Bruton tyrosine kinase (BTK) inhibitor ibrutinib with or without rituximab was superior to standard-of-care,...

Rivaroxaban Reduces Thrombotic Risk in Patients Undergoing Cancer Treatment

Primary prevention with the direct oral anticoagulant (DOAC) rivaroxaban reduced venous thromboembolism (VTE) and VTE-related mortality in patients with cancer, according to results from...

New Sickle Cell Disease Screening Test Is Highly Accurate – and Inexpensive

Editor's note: On March 11, 2019, the editors of Blood retracted this abstract, after a co-author stated it was submitted without his consent. In a population of...

Ibrutinib Versus FCR: A “Paradigm Shift” for Younger Patients With Treatment-Naïve CLL

In patients with previously untreated chronic lymphocytic leukemia (CLL), treatment with an ibrutinib-based therapy improved progression-free survival (PFS) and overall survival (OS), compared with...

Is Daratumumab Plus Lenalidomide-Dexamethasone a New Standard for Transplant-Ineligible Myeloma?

Adding daratumumab to standard combination of lenalidomide and dexamethasone (Rd) reduced the risk of disease progression and death by 44 percent in patients with...

New Tool Provides Simple Approach to Interrupting Direct Oral Anticoagulants for Surgery

Researchers have developed a “simple, standardized, easy-to-use” strategy to guide decisions about interrupting direct oral anticoagulants (DOACs) in patients with atrial fibrillation (AF) scheduled...

Can Voxelotor Offer New HOPE for Sickle Cell Disease?

Treatment with voxelotor led to a dose-dependent increase in hemoglobin (Hb) levels in patients with sickle cell disease (SCD), with most patients responding to...

Ixazomib Maintenance Prolongs Progression-Free Survival in Newly Diagnosed Multiple Myeloma

For the substantial portion of patients with multiple myeloma (MM) who relapse following autologous hematopoietic cell transplantation (AHCT), maintenance therapy with ixazomib could offer...

Iron Chelation Therapy With Deferasirox Improves Survival Over Placebo in Lower-Risk MDS

In patients with lower-risk myelodysplastic syndromes (MDS) and iron overload (IO), treatment with iron chelation therapy (ICT) deferasirox was associated with longer event-free survival...

Elotuzumab Combination Prevents Progression from Smoldering to Symptomatic Myeloma

In a phase II trial of patients with high-risk smoldering multiple myeloma (SMM), 84 percent of participants responded to treatment with elotuzumab, lenalidomide, and...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.